Abstract
The so-called “silver tsunami” is a metaphor that the individuals 65 and older represent the most rapidly growing segment of the Western world population.
Aging is an ongoing process that leads to the loss of functional reserve of multiple organ systems, increased susceptibility to stress, it is associated with increased prevalence of chronic disease, and functional dependence. Determined by a combination of genetic and environmental factors, this process is highly individualized and poorly reflected in chronologic age. The heterogeneity and the complexity of the older old population represent the main challenge to the treatment of cancer in those patients. We should discern "fit" elderly in whom standard cancer treatment appears to be comparable to a younger population and “unfit” or "frail" elderly, in which the risks of the treatment may overwhelm potential benefits.
There are many aspects that have to be assessed before treating an elderly patient, or before to choose the treatment itself. In our review we will try to explain and describe the meaning and the most important aspects related to the oldest old complex patients, and how to manage those patients.
Keywords: Cancer, elderly, oldest old, sarcopenia, fatigue, frailty, CGA.
Current Pharmaceutical Design
Title:Treating Cancer in Older and Oldest Old Patients
Volume: 21 Issue: 13
Author(s): G. Colloca, A. Corsonello, E. Marzetti, L. Balducci, F. Landi, M. Extermann, G. Scambia, M. Cesari, I. Carreca, S. Monfardini and R. Bernabei
Affiliation:
Keywords: Cancer, elderly, oldest old, sarcopenia, fatigue, frailty, CGA.
Abstract: The so-called “silver tsunami” is a metaphor that the individuals 65 and older represent the most rapidly growing segment of the Western world population.
Aging is an ongoing process that leads to the loss of functional reserve of multiple organ systems, increased susceptibility to stress, it is associated with increased prevalence of chronic disease, and functional dependence. Determined by a combination of genetic and environmental factors, this process is highly individualized and poorly reflected in chronologic age. The heterogeneity and the complexity of the older old population represent the main challenge to the treatment of cancer in those patients. We should discern "fit" elderly in whom standard cancer treatment appears to be comparable to a younger population and “unfit” or "frail" elderly, in which the risks of the treatment may overwhelm potential benefits.
There are many aspects that have to be assessed before treating an elderly patient, or before to choose the treatment itself. In our review we will try to explain and describe the meaning and the most important aspects related to the oldest old complex patients, and how to manage those patients.
Export Options
About this article
Cite this article as:
Colloca G., Corsonello A., Marzetti E., Balducci L., Landi F., Extermann M., Scambia G., Cesari M., Carreca I., Monfardini S. and Bernabei R., Treating Cancer in Older and Oldest Old Patients, Current Pharmaceutical Design 2015; 21 (13) . https://dx.doi.org/10.2174/1381612821666150130122536
DOI https://dx.doi.org/10.2174/1381612821666150130122536 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Mesenchymal Stem Cell Therapy for Acetaminophen-related Liver Injury: A Systematic Review and Meta-analysis of Experimental Studies <i>In Vivo</i>
Current Stem Cell Research & Therapy Lipoproteins, Stroke and Statins
Current Vascular Pharmacology The Fetal Cardiac Function
Current Cardiology Reviews Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Antiapoptotic Effect of Novel Compound from Herba leonuri-Leonurine (SCM-198): A Mechanism Through Inhibition of Mitochondria Dysfunction in H9c2 Cells
Current Pharmaceutical Biotechnology The Multiple Electrocardiographic Manifestations of Ventricular Repolarization Memory
Current Cardiology Reviews Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Differentiation of Mesenchymal Stem Cells from Humans and Animals into Insulin-producing Cells: An Overview <i>In Vitro</i> Induction Forms
Current Stem Cell Research & Therapy Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Nitrogen Biobank for Cardiovascular Research
Current Cardiology Reviews Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Systems Biology and Biomechanical Model of Heart Failure
Current Cardiology Reviews